Tapinarof Cream Shows Strong Results Across Pediatric Atopic Dermatitis Ages
New look at tapinarof cream for eczema in kids and adults
A recent analysis of two large clinical trials looked at how well VTAMA (tapinarof) cream 1% worked for people with atopic dermatitis, the medical name for eczema. The results were presented at the 2026 Society for Pediatric Dermatology Annual Meeting, and the company behind the drug shared a summary of the findings. (Source: Organon press release; presentation at the Society for Pediatric Dermatology Annual Meeting.)
Quick summary
The pooled data combined results from the phase 3 ADORING 1 and ADORING 2 trials. About 80% of the people in those trials were children. Across all pediatric age groups and in adults, the cream showed better improvement in eczema than the vehicle cream (the non‑active base used as a comparison). The difference appeared as early as week 1 and continued through the trial. (Source: Organon press release; ADORING 1 and 2 pooled analysis presented at the 2026 meeting.)
What the study looked at
The researchers combined the results from two phase 3 trials to see how different age groups responded. Phase 3 trials are typically large studies done to understand if a treatment works and is safe in many people. The analysis separated results by pediatric age groups and also included adults.
Dr. Linda Stein Gold, director of dermatology clinical research at Henry Ford Health and an investigator in the tapinarof program, discussed the findings at the meeting. She also has a reported connection with Organon Health Partner, which is noted in the presentation. (Source: Presentation by Linda Stein Gold; Organon press materials.)
Key findings for parents and families
Every pediatric age group in the pooled data showed a statistically significant improvement compared with the vehicle cream. That means the measured improvements were unlikely to be due to chance when compared with the non‑active cream used in the trials.
That said, the trials were not designed to compare one age group directly against another, so we can’t say which age group had the biggest benefit. The important takeaway was that each child age group did better than the vehicle.
Why it mattered that the cream was tolerated well
Tolerability means how well people (and their caregivers) can use a treatment without uncomfortable side effects like stinging, burning, or irritation. The presenters noted that tolerability played a big role in the results for younger children.
If a cream irritates a child or is hard to apply, caregivers may skip doses or stop using it. According to the presentation, VTAMA was generally well tolerated, which likely helped families stick with the treatment and may have contributed to the good results seen in the trials. (Source: Presentation and Organon report.)
Early improvement and family impact
Families often want to see results quickly, especially when eczema affects a child’s sleep, comfort, and daily routine. The pooled analysis reported that the group using tapinarof began to separate from the vehicle group as early as week 1, and that separation continued through the trial period. That early change can help build confidence that a treatment is working.
What this does and doesn’t prove
This analysis suggests VTAMA may help some people with atopic dermatitis, including children. However, the findings come from company‑reported pooled trial data presented at a conference. The investigator who presented the data also worked on the trial program and has ties to the company, which is a common disclosure in industry‑ studies. These are important details to keep in mind when interpreting results. (Source: Organon press release and conference presentation.)
If you’re thinking about this medicine for your child or yourself, talk with your primary care provider or a dermatologist. They can explain whether this treatment is a reasonable option based on the severity of eczema, other health factors, and available evidence.
Tracking skin changes
Keeping a simple photo diary or notes about redness, itch, sleep, and areas affected can help you and your doctor see whether a treatment is helping. This can be especially useful when a treatment is started and you want to notice early changes.
When to see a doctor
See a healthcare professional if a rash is spreading quickly, becomes painful, shows signs of infection (increasing redness, warmth, pus), bleeds, or if your child’s sleep or daily activities are seriously affected. If you’re unsure whether a new treatment is right, ask a dermatologist for guidance.
Disclaimer
This article summarizes trial results presented at a medical meeting and a company report. It is informational and not medical advice. Treatment decisions should be made with a healthcare provider.
Sources
- New analysis of phase 3 pooled data for Organon’s VTAMA (tapinarof) cream, 1%, demonstrates early, consistent improvements in atopic dermatitis patients across pediatric age groups and in adults. Organon press release. Accessed July 24, 2026. https://www.organon.com/news/new-analysis-of-phase-3-pooled-data-for-organons-vtama-tapinarof-cream-1-demonstrates-early-consistent-improvements-in-atopic-dermatitis-patients-across-pediatric-age-groups-and-in/ (Source: Organon press release)
- Presentation of pooled phase 3 ADORING 1 and ADORING 2 data at the 2026 Society for Pediatric Dermatology Annual Meeting. (Source: Society for Pediatric Dermatology meeting presentation)